

## Benlysta Order Form (belimumab)

Plimumab) FAX TO: 972.499.9210

IIIusioii	(	,	
PATIENT INFORMATION			
Patient Name:	DOB: Ph	one:Sex	c: M F Ht: Wt: lbs kg
Primary Language:	Allergies:		
Patient Preferred Location:			
<icd 10="" code="" required=""></icd>	DIAGNOSIS & CLIN	ICAL INFORMATION	
ICD 10 Code  M32.10 Systemic Lupus Erythematosus, Organ or System Involvement Unspecified  M32.15 Tubulo-interstitial Nephropathy in Systemic Lupus Erythematosus  Other:			
<u>REQUIRED</u> : Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy. <u>LAB RESULTS</u> : Positive autoantibody results: i.e. Anti-dsDNA, Antinuclear Antibody (ANA), Anti-Smith.			
	PRESCI	RIPTION	
Pre-Medications  Acetaminophen: 650 mg PO Cetirizine: 10 mg PO Diphenhydramine: 25 mg PO Diphenhydramine: 25 mg IVP Famotidine: 20 mg PO Methylprednisolone: 125 mg SIVP Other: BENLYSTA (belimumab) Loading Dose			
IV: Infuse 10 mg/kg in 250 mL of 0.9% Sodium Chloride over at least 60 minutes at weeks 0, 2, and 4  Maintenance Dose IV: Infuse 10 mg/kg in 250 mL of 0.9% Sodium Chloride over at least 60 minutes every 4 weeks for one year			
Patient Weight: lbs or kg			
Is the patient on any other disease modi	fying therapy? Yes	No	
Post Treatment Observations: The patient is observed for 30 minutes following the first administration.			
Adverse Events: In the event of an adverse protocol.  Comments:	se reaction occurring at a M	edix Infusion suite, utilize the	Medix Infusion adverse reactions
PRESCRIBER INFORMATION			
Prescriber Name:		Signature:	
Date: NPI #:			
Supervising Physician:			(If Applicable)
Address:	City:		_ State: Zip:
Contact Name:	Phone:	Fax:	Email: